Number of the records: 1
Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives
- 1.
SYSNO ASEP 0555820 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives Author(s) Mitrović, Marko (FGU-C)
Sistilli, Gabriella (FGU-C)
Horáková, Olga (FGU-C) RID, ORCID
Rossmeisl, Martin (FGU-C) RID, ORCIDArticle number e13650 Source Title European Journal of Clinical Investigation. - : Wiley - ISSN 0014-2972
Roč. 52, č. 3 (2022)Number of pages 19 s. Language eng - English Country US - United States Keywords krill oil ; marine phospholipids ; n-3 polyunsaturated fatty acids ; non-alcoholic fatty liver disease ; obesity OECD category Endocrinology and metabolism (including diabetes, hormones) R&D Projects GA17-11027S GA ČR - Czech Science Foundation (CSF) Method of publishing Limited access Institutional support FGU-C - RVO:67985823 UT WOS 000679928600001 EID SCOPUS 85111860948 DOI 10.1111/eci.13650 Annotation Prevalence of non-alcoholic fatty liver disease (NAFLD) increases in line with obesity and type 2 diabetes, and there is no approved drug therapy. Polyunsaturated fatty acids of n-3 series (omega-3) are known for their hypolipidaemic and anti-inflammatory effects. Existing clinical trials suggest varying effectiveness of triacylglycerol- or ethyl ester-bound omega-3 in the treatment of NAFLD, without affecting advanced stages such as non-alcoholic steatohepatitis. Preclinical studies suggest that the lipid class used to supplement omega-3 may determine the extent and nature of their effects on metabolism. Phospholipids of marine origin represent an alternative source of omega-3. The aim of this review is to summarise the available evidence on the use of omega-3 phospholipids, primarily in obesity-related NAFLD, and to outline perspectives of their use in the prevention/treatment of NAFLD. A PubMed literature search was conducted in May 2021. In total, 1088 articles were identified, but based on selection criteria, 38 original papers were included in the review. Selected articles describing the potential mechanisms of action of omega-3 phospholipids have also been included. Preclinical evidence clearly indicates that omega-3 phospholipids have strong antisteatotic effects in the liver, which are stronger compared to omega-3 administered as triacylglycerols. Multiple mechanisms are likely involved in the overall antisteatotic effects, involving not only the liver but also adipose tissue and the gut. Robust preclinical evidence for strong antisteatotic effects of omega-3 phospholipids in the liver should be confirmed in clinical trials. Further research is needed on the possible effects of omega-3 phospholipids on advanced NAFLD. Workplace Institute of Physiology Contact Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Year of Publishing 2023 Electronic address https://doi.org/10.1111/eci.13650
Number of the records: 1